Trial Profile
A Study to Evaluate the In Vivo Effect of Interferon Beta-1a (Avonex) Therapy on B-Cell Regulation of Inflammatory Response in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 10 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology